Written by Andrea Bernardini, Associate Consultant & Marco Sancandi, Analyst Contacts: [email protected]; [email protected] In a significant step forward for healthcare in Italy, the National Rare
Written by: Srishti Gupta, PhD; Senior Consultant Contact: [email protected] In March 2023, the Food and Drug Administration (FDA) published, a first of its kind, draft
By Marco Sancandi, PhD; Analyst On the 31st of January 2023, the 6th joint report from the Orphan Drugs Observatory and the Italian Society of
By Fisentzos Stylianou, PhD; Senior Analyst The UK will be the first country to introduce a regulatory framework for innovative medicines manufactured at the point
By Fisentzos Stylianou, PhD; Senior Analyst Contact: [email protected] “I can say on behalf of the G-BA that it is possible that we will recognise some
By Fisentzos Stylianou, PhD Contact: [email protected] NICE’s launches a real-world evidence framework Closing knowledge gaps and advancing patient access to innovations are major aims of the
London, United Kingdom, April 27, 2022- Leading specialist market access consultancy Partners4Access analyst’s have been awarded ‘Highly Commended’’ Analyst Team of the Year 2022 by
By Fisentzos Stylianou, PhD Contact: [email protected] One of the main healthcare challenges raised by the European Medicines Agency’s (EMA) network strategy to 2025 is the
By Chloe Sheppard, Associate Consultant Contact: [email protected] A major milestone in the creation of pan-European joint health technology assessment (HTA) was reached in January this
